Approval of DUPIXENT® (dupilumab) to treat atopic dermatitis in Europe
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has granted marketing authorization for DUPIXENT®(dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are...
Read More